Across TCGA pan-cancer cohorts, TMEM200C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM200C data layer compared with 22 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TMEM200C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM200C expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

KIRC, BRCA, and LIHC are the cancer types where TMEM200C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.133	0.805	<.001	42	view →
BRCA	OS	Median	All	0.113	0.578	.001	24	view →
LIHC	OS	Median	All	0.105	0.786	<.001	24	view →
HNSC	DFS	Median	All	1.000	0.317	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TMEM200C tumor-vs-normal RNA expression · all TMEM200C data types